2025-05-12 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals Inc. (RXRX) based on the provided data, formatted as requested.

## RXRX Stock Analysis: Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to discover and develop novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

**Numbers:**

*   **RXRX Cumulative Return:** -59.08%
*   **VOO Cumulative Return:** 19.65%
*   **Absolute Divergence:** -78.73% (RXRX underperformed VOO by 78.73% since inception data)
*   **Relative Divergence:** 1.0 (Indicates RXRX's underperformance is near its worst historical level relative to VOO within the given timeframe.)

**Analysis:**

RXRX has significantly underperformed the S&P 500 (VOO) over the period represented by the cumulative return data.  The relative divergence suggests this underperformance is near the lowest point within the historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD  | Alpha  | Beta  | Cap(B) |
|------------|-------|------|--------|-------|--------|
| 2021-2023  | 5.0%  | 73.6% | -12.0% | -0.0  | 4.0    |
| 2022-2024  | 0.0%  | 73.6% | -22.0% | 0.0   | 2.7    |
| 2023-2025  | -8.0% | 73.6% | -26.0% | -0.0  | 1.8    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate has decreased from 5.0% in 2021-2023 to -8.0% in 2023-2025, indicating declining performance.
*   **MDD:** The Maximum Drawdown is consistently high at 73.6% across all periods, suggesting significant risk and volatility.
*   **Alpha:** Alpha is negative and decreasing, indicating underperformance relative to the market (S&P 500).
*   **Beta:** Beta is near zero, suggesting low correlation with the overall market.
*   **Cap:** The company's market capitalization has decreased from $4.0 billion to $1.8 billion, reflecting a decline in investor confidence or company value.

### 2. Recent Price Action

**Numbers:**

*   **Current Price:** $4.39
*   **Last-market Data:** {'price': 4.33, 'previousClose': 4.39, 'change': -1.37}
*   **5-day Moving Average:** 4.64
*   **20-day Moving Average:** 5.31
*   **60-day Moving Average:** 6.34

**Analysis:**

The current price is below all three moving averages (5-day, 20-day, and 60-day), indicating a downtrend. The Last-market data shows the stock closed lower than the previous day, which adds negative sentiment.

### 3. Market Risk Indicators & Expected Return

**Numbers:**

*   **Market Risk Indicator (MRI):** 0.3707 (Low Risk)
*   **RSI:** 31.38 (Approaching oversold territory)
*   **PPO:** -2.14
*   **Delta_Previous_Relative_Divergence:** -5.0 (Negative trend)
*   **Expected Return:** -3719.7%

**Analysis:**

*   The RSI suggests the stock is nearing oversold territory, which *could* indicate a potential for a short-term bounce.
*   The PPO (Percentage Price Oscillator) is negative, confirming the downtrend.
*   The negative Delta_Previous_Relative_Divergence indicates a recent short-term decline in relative performance.
*   The significantly negative Expected Return suggests a very pessimistic outlook for long-term returns relative to the S&P 500.
*   The Last-market data shows a price decrease, indicating ongoing volatility and potential short-term issues.

### 4. Recent News & Significant Events

*   **May 8, 2025:** Major business developments, regulatory changes, or market events.
*   **May 10, 2025:** Analysts discussing recent performance and outlook.
*   **May 11, 2025:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **May 9, 2025:** Market experts highlight risks and opportunities, advising monitoring of news and announcements.

**Analysis:**

The recent news suggests that RXRX is experiencing significant changes and volatility, requiring careful monitoring of company announcements and market developments.

### 5. Recent Earnings Analysis

| 날짜        | EPS   | 매출         |
|-------------|-------|--------------|
| 2025-05-05  | -0.50 | 0.01 B$      |
| 2024-11-06  | -0.34 | 0.03 B$      |
| 2024-08-08  | -0.40 | 0.01 B$      |
| 2024-05-09  | -0.39 | 0.01 B$      |
| 2025-05-05 | -0.39 | 0.01 B$      |

**Analysis:**

The company has consistently reported negative EPS over the last several quarters. Revenue has been relatively low and inconsistent, suggesting challenges in monetization.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-03-31   | $0.01B   | -47.31%       |
| 2024-12-31   | $0.00B   | -183.62%      |
| 2024-09-30   | $0.03B   | 53.69%        |
| 2024-06-30   | $0.01B   | 36.14%        |
| 2024-03-31   | $0.01B   | 17.23%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-03-31   | $0.93B    | -21.68%  |
| 2024-12-31   | $1.03B    | -17.29%  |
| 2024-09-30   | $0.52B    | -18.27%  |
| 2024-06-30   | $0.58B    | -16.69%  |
| 2024-03-31   | $0.40B    | -22.78%  |

**Analysis:**

*   **Revenue:** Fluctuating revenue indicates inconsistent business performance.
*   **Profit Margin:** Primarily negative profit margins highlight a lack of profitability.
*   **Equity:** Equity levels have fluctuated, reflecting changes in the company's net assets.
*   **ROE:** Negative Return on Equity (ROE) confirms the company's inability to generate profit from shareholder equity.

### 7. Overall Summary

RXRX is facing significant challenges. It has underperformed the market substantially, with consistently negative earnings and fluctuating revenue.  The recent news indicates potential volatility and significant changes within the company. While the RSI suggests a possible short-term bounce, the overall outlook is pessimistic, reflected in the extremely negative expected return. The company's financial health, characterized by negative profit margins and ROE, raises concerns about its long-term sustainability. The high MDD and negative Alpha values suggest this is a high risk stock.

**Disclaimer:** This analysis is based solely on the provided data and should not be considered financial advice. Consult with a qualified financial advisor before making any investment decisions.
